Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
CTX-100 (formerly ETX-100) (hyaluronic acid)
Drug
Lead sponsor
Turino, Gerard, M.D.
Individual
Eligibility
40 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Tucson, Arizona • New York, New York
Conditions
Breast Cancer, Stage 0 Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Stage 0 Breast Carcinoma, Stage II Breast Carcinoma, Stage III Breast Carcinoma, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions
Revaree Plus
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Completed Not applicable Interventional Results available

Clinical Evaluation of a New Viscoelastic for Cataract Surgery

NCT00972621
Conditions
Cataract
Interventions
Vitrax II, Viscoat
Device
Lead sponsor
Abbott Medical Optics
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Santa Ana, California
Conditions
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreatic Neoplasms
Interventions
PEGPH20, Pembrolizumab
Drug · Biological
Lead sponsor
Pancreatic Cancer Research Team
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Gilbert, Arizona • Los Angeles, California • New Brunswick, New Jersey + 2 more
Completed Phase 4 Interventional Accepts healthy volunteers

Skin Barrier Function and Inflammation in Aging: The BIA Study

NCT06750653
Conditions
Inflammation, Skin Inflammation, Aging
Interventions
CeraVe Moisturizing Cream, Vaseline
Other · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
70 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Conditions
Recovery Following Partial Medial Meniscectomy
Interventions
Mesenchymal Stem Cells, Hyaluronan
Drug
Lead sponsor
Mesoblast International Sàrl
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
8
States / cities
Los Angeles, California • Vero Beach, Florida • Chicago, Illinois + 5 more
Conditions
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
Interventions
EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy)
Drug
Lead sponsor
enGene, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 43 more
Conditions
Osteoarthritis, Post-traumatic Osteoarthritis
Interventions
amobarbital/Gel-One (one dose), Placebo (single dose), amobarbital/Gel-One (two doses), Placebo (two doses)
Drug
Lead sponsor
J L Marsh
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Not yet recruiting Phase 1Phase 2 Interventional

XVIE to Treat Androgenetic Alopecia (AGA)

NCT07482423
Conditions
Androgenetic Alopecia
Interventions
Decellularized allogeneic human amniotic fluid, Sodium chloride 0.9% injectable solution
Biological · Drug
Lead sponsor
Restore Biologics Holdings, Inc. dba Xtressé
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Orlando, Florida • Marriottsville, Maryland